Recent Finacing
Recent Raise
Lucence develops LiquidHALLMARK, an amplicon-sequencing blood-based genomic assay that detects cancer-related mutations and oncogenic viruses for screening, diagnosis, treatment selection, and monitoring across multiple cancer types.
